PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase

Blood

Volumn 129, Issue 17, 2017, Pages 2437-2442

  Kwong, Yok Lam ^a   Chan, Thomas S Y ^a   Tan, Daryl ^b,c   Kim, Seok Jin ^d   Poon, Li Mei ^e   Mow, Benjamin ^f   Khong, Pek Lan ^a   Loong, Florence ^a   Au Yeung, Rex ^a   Iqbal, Jabed ^c   Phipps, Colin ^b,c   Tse, Eric ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b RAFFLES HOSPITAL   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e National University Cancer Institute   (Singapore)

^f MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; PEMBROLIZUMAB; VIRUS DNA; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; FOLLOW UP; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; REFRACTORY NK T CELL LYMPHOMA; SKIN GRAFT; TREATMENT RESPONSE; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; DRUG EFFECT; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; T LYMPHOCYTE; TREATMENT FAILURE; VIROLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASPARAGINASE; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SUSTAINED VIROLOGIC RESPONSE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 85018758635     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-12-756841     Document Type: Article

References (21)

1. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997-5005.
2. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410-4416.
3. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973-2980.
4. Tse E, Kwong YL. Diagnosis and management of extranodal NK/T cell lymphoma nasal type. Expert Rev Hematol. 2016;9(9):861-871.
5. Tse E, Kwong YL. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med. 2015;47:e136.
6. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462-3473.
7. Kwong YL, Lopes D, Khong PL. Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma. Br J Haematol. 2017;176(1):131-132.
8. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-3058.
9. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
10. 18F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center. J Nucl Med. 2014;55(6):911-916.
11. Kwong YL, Pang AW, Leung AY, Chim CS, Tse E. Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014;28(4):865-870.
12. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489-2496.
13. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480-489.
14. Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777-2789.
15. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12):2186-2194.
16. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243-249.
17. Kanakry JA, Hegde AM, Durand CM, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127(16):2007-2017.
18. Kim SJ, Choi JY, Hyun SH, et al; Asia Lymphoma Study Group. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. Lancet Haematol. 2015;2(2):e66-e74.
19. Kwong YL. Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. Ann Hematol. 2016;95(7):1191-1192.
20. Chan TS, Khong PL, Kwong YL. Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol. 2016;95(11):1913-1915.
21. Davids MS, Kim HT, Bachireddy P, et al; Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375(2):143-153.